|
| Press Releases |
|
 |
|
| Friday, August 8, 2025 |
|
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan |
| Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON'. more info >> |
|
| Tuesday, August 5, 2025 |
|
|
NEFECON(R) Receives NMPA Approval for Production Expansion in China, as Everest Medicines Accelerates Accessibility and Capacity Efforts |
| Everest Medicines (HKEX 1952.HK) today announced that the supplemental application for the production expansion of NEFECON has been officially approved by China's National Medical Products Administration (NMPA). more info >> |
|
| Saturday, August 2, 2025 |
|
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies |
| Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash. more info >> |
|
| Friday, July 25, 2025 |
|
|
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million |
| Everest Medicines (HKEX 1952.HK, Everest or the " Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the "Sellers"), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue. more info >> |
|
| Friday, July 4, 2025 |
|
|
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation |
| Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company's progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases. more info >> |
|
| Thursday, June 12, 2025 |
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances |
| At the 62nd Congress of the European Renal Association (ERA 2025), Everest Medicines presented new results findings on both NEFECON(budesonide delayed release capsules), the world's first and only approved therapy that directly targets the underlying cause of IgA nephropathy (IgAN), and EVER001, a next-generation covalent reversible BTK inhibitor. more info >> |
|
| Monday, June 9, 2025 |
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025 |
| At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy (pMN). more info >> |
|
| Wednesday, May 7, 2025 |
|
|
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China |
| Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). more info >> |
|
| Tuesday, April 22, 2025 |
|
|
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the 'Stock Exchange') has approved the Company's application to remove the "B" marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. more info >> |
|
| Friday, March 7, 2025 |
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation |
| Everest Medicines' stock (1952.HK) surged today, opening higher and maintaining strong momentum throughout the trading day. By market close, the stock had risen 20.12% to HK$60.6, bringing the company's total market capitalization to HK$19.791 billion. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Open World and VerifyMe Sign Merger Agreement
Feb 12, 2026 21:00 HKT/SGT
|
|
|
U.S. Polo Assn. Unveils Experiential USPA Shop Flagship at the USPA National Polo Center
Feb 12, 2026 20:00 HKT/SGT
|
|
|
Radisson Highlights Developing Vein Model at O'Brien Gold Project with Implications for Future Growth and Mine Planning
Feb 12, 2026 19:59 HKT/SGT
|
|
|
Lockheed Martin and Fujitsu Formalize Industrial Collaboration for Japan Defense
Feb 12, 2026 19:59 JST
|
|
|
Meiji and Fujitsu launch world's first rRAFU(TM) pilot to assess future malnutrition and frailty risk
Feb 12, 2026 16:09 JST
|
|
|
Airwheel Announces Expanded Global Deployment of AI-Enabled Rideable Smart Electric Cabin Suitcase
Feb 12, 2026 11:30 HKT/SGT
|
|
|
Fujitsu Group starts manufacturing sovereign AI servers in Japan to enhance digital sovereignty
Feb 12, 2026 12:13 JST
|
|
|
Casa Minerals Inc Announces Closing of Oversubscribed Private Placement, and Retains European Marketing Firm for Investor Awareness Services
Feb 12, 2026 07:30 HKT/SGT
|
|
|
GTJAI Sponsored Axera's Listing on the Main Board of HKEX
Feb 11, 2026 19:40 HKT/SGT
|
|
|
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
Feb 11, 2026 19:00 HKT/SGT
|
|
|
Focus Graphite Engages Dr. Reuter Investor Relations to Expand German and European Capital Markets Presence
Feb 11, 2026 18:29 HKT/SGT
|
|
|
CleverTap Recognized as a Leader in Latest Gartner Magic Quadrant for Personalization Engines
Feb 11, 2026 14:30 HKT/SGT
|
|
|
Premiere of Three-Row Highlander BEV in North America
Feb 11, 2026 14:25 JST
|
|
|
The 18th Annual Global CSR & ESG Summit & Awards 2026 Arrives in Bangkok -- Igniting Asia with AI, Energy & ESG Innovation on 23 April 2026
Feb 11, 2026 11:39 HKT/SGT
|
|
|
U.S. Marine Corps Selects GA-ASI for MUX TACAIR Collaborative Combat Aircraft Program
Feb 11, 2026 08:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
